Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Serplulimab |
| Trade Name | |
| Synonyms | HLX10|HLX-10|HLX 10 |
| Drug Descriptions |
Serplulimab (HLX10) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513). |
| DrugClasses | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| CAS Registry Number | 2231029-82-4 |
| NCIT ID | C156738 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Carboplatin + Etoposide + Serplulimab | Carboplatin Etoposide Serplulimab | 0 | 2 |
| Carboplatin + Nab-paclitaxel + Serplulimab | Carboplatin Nab-paclitaxel Serplulimab | 0 | 1 |
| Cisplatin + Etoposide + Serplulimab | Cisplatin Etoposide Serplulimab | 0 | 1 |
| HLX60 + Serplulimab | HLX60 Serplulimab | 0 | 1 |
| Serplulimab | Serplulimab | 0 | 0 |